MIST Stock Forecast & Price Target

Milestone Pharmaceuticals is attractive because CARDAMYST has already established a validated, differentiated at-home rescue model for PSVT, with phase 3 data showing rapid conversion versus placebo and commercial traction that should improve as coverage rises above 50% and Medicare begins contributing in 2027. The China NMPA approval adds ex-U.S. optionality and non-dilutive economics, including a $2M milestone, up to $98M more in milestones, and tiered royalties of up to 18%, while also reinforcing etripamil’s clinical and regulatory profile in a market with an estimated 3M-6M diagnosed PSVT patients. Beyond PSVT, the ongoing AFib-RVR program could materially expand the addressable market, and at a roughly $130M EV the stock appears to leave room for both improving U.S. launch execution and longer-term pipeline upside.

Milestone Pharmaceuticals is viewed negatively because Cardamyst’s launch has been weaker than expected, with soft prescription volume, prescriber productivity, and reported sales failing to validate the broad PSVT opportunity or the ~$250-300M peak base case. The company now faces commercial execution risk rather than regulatory risk, as uptake may remain concentrated among electrophysiologists, while cardiologists need more education, repeat writing stays limited, and most prescriptions still rely on copay assistance with net revenue per Rx expected to remain below $500 for the rest of 2026. In addition, its heavy dependence on Cardamyst creates funding, reimbursement, and product-concentration risk, and the AFib-RVR program adds another layer of regulatory uncertainty because self-administration, episode recognition, and a potentially noisy patient-reported endpoint could weaken the data package.